Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn Pharma
Apr 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
CareDx has acquired Naveris, a diagnostics imaging business in California, for $160 million. Naveris develops oncology diagnostics tools that support clinical decision-making and imaging-based workflows for cancer care. CareDx acquisitions in diagnostics imaging aim to expand its platform capabilities and strengthen its healthcare M&A portfolio in oncology testing. The strategic acquisition is structured as a platform acquisition and is part of broader CareDx acquisitions. The deal was announced and is expected to close following customary conditions for healthcare M&A.
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Avalyn Pharma
Apr 30, 2026
Avalyn Pharma
Apr 30, 2026
Parexel→Vitrana
Apr 29, 2026
Chiesi Group→KalVista Pharmaceuticals
Apr 29, 2026
CareDx→Naveris
Apr 29, 2026